DermTech 2.0 is a platform technology company that provides genomic analysis of skin samples collected non-invasively using its proprietary Smart Sticker®. DermTech 2.0 develops and markets products, including the DermTech Melanoma Test, to facilitate the assessment of melanoma and other skin diseases, and offers DermTech Stratum, precision biomarker services for biopharmaceutical and research partners.
The DermTech Melanoma Test (DMT)
DermTech Stratum
The DMT in Dermatology
The DMT is primarily used by dermatology specialists for the assessment of equivocal pigmented lesions.
Stratum Biopharma Services
Partnering services make the Smart Sticker® platform, high-complexity CLIA laboratory and DermTech 2.0’s expertise available to biopharma partners and central laboratories.
The DMT in Primary Care
The DMT is also available to qualified primary care physicians as a rule-out test to guide dermatology specialty referrals.
Stratum Development
Internal and partnered development of non-invasive genomic tests for indications including Cutaneous T-Cell Lymphoma, Basal Cell Carcinoma, atopic dermatitis, psoriasis and psoriatic arthritis, and the Luminate UV skin damage test.
The DermTech Melanoma Test (DMT)
The DMT in Dermatology
The DMT is primarily used by dermatology specialists for the assessment of equivocal pigmented lesions.
The DMT in Primary Care
The DMT is also available to qualified primary care physicians as a rule-out test to guide dermatology specialty referrals.
DermTech Stratum
Stratum Biopharma Services
Stratum Development
Internal and partnered development of non-invasive genomic tests for indications including Cutaneous T-Cell Lymphoma, Basal Cell Carcinoma, atopic dermatitis, psoriasis and psoriatic arthritis, and the Luminate UV skin damage test.
Led by a dedicated team of dermatologists, dermatopathologists and experienced laboratory professionals, DermTech 2.0 is committed to quality and customer support.



